Executive Summary
An email from the PTAB Director notifies Google and Cerence that Director Review requests have been filed for IPR2024‑01464 and IPR2024‑01465, outlining a five‑page, five‑business‑day response limit and prohibiting new evidence.
Related Cases
Apple Inc.vsSmith Interface Technologies, LLC
The PTAB issued a Final Written Decision finding numerous claims of Smith Interface Technologies unpatentable over the combination of Hotelling, Martyn, and Cho. The Board adopted a specific definition for POSITA, requiring computer science expertise with professional GUI experience.
Apple Inc.vsApex Beam Technologies LLC
Apple petitions an IPR to invalidate 20 claims of Apex Beam’s 11,374,721 patent covering grant‑free uplink transmission, citing Lee, Freda and Ly as obviousness prior art.
Samsung Electronics Co., Ltd. et al.vsCerence Operating Company
Samsung has filed an IPR petition seeking cancellation of all 20 claims of Cerence’s ’671 patent, arguing they are obvious over existing text‑to‑speech technologies. The petition also argues that discretionary factors favor instituting the review.
HIKMA PHARMACEUTICALS USA INC.vsAxsome Malta Ltd. et al.
Hikma Pharmaceuticals filed a joint motion with Axsome Malta to terminate IPR2024‑01418 after reaching a confidential settlement, resulting in dismissal of the petition before institution.
Embody, Inc. et al.vsLifeNet Health
Embody and Zimmer Biomet successfully secured institution in this IPR against LifeNet Health's '223 patent. The Board found a reasonable likelihood that claims related to collagen scaffolds with specific FFT analysis characteristics are unpatentable over prior art references like Huang2 and Lee.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.